Displaying 41 - 50 of 88 for Cancer - All
  • MABEL Study (H-35253)
    • In this study, we want to find out if we can use banked MABEL CTLs to treat HD or NHL, T/NK-lymphoproliferative disease and severe chronic active Epstein Barr Virus (CAEBV).
  • MAGNIFY Study (H-35785)
    • The purpose of this study is to learn how well the combination of lenalidomide (an investigational drug) and a medicine called rituximab works in controlling some forms of non-Hodgkin lymphoma (NHL).
  • Malignant Pleural Mesothelioma Treatment Study (H-36460)
    • The primary objective of this study is to to determine the maximum tolerated dose of intrathoracic administration of pemetrexed when given in conjunction with cisplatin in patients with resectable MPM .
  • Mesothelioma Study (H-36952)
    • This study combines immunotherapy and surgery for the treatment of mesothelioma.
  • Mesothelioma Study (H-38140)
    • The purpose of this study is to assess whether the study drug anetumab ravtansine is more effective than a standard treatment with vinorelbine in mesothelioma patients with this type of mesothelin overexpression
  • METRIC Study (H-34400)
    • Patients with "Triple Negative Breast Cancer" that are gpNMB over-expressing are invited to participate in a new drug study to see if CDX-011 (glembatumumab vedotin, an antibody-drug conjugate) is effective in treating patients with this diagnosis.
  • MOHEL Study (H-8701)
    • Subjects are being asked to participate in this study because treatment of their disease requires them to receive a stem cell transplant.
  • Multiple Myeloma Study (H-33837
    • The purpose of this study is to explore a drug combination alone or when combined with autologous stem cell transplantation to see what side effects it may have and how well it works for treatment of newly diagnosed multiple myeloma.
  • Neratinib +/- Fulvestrant in Metastatic HER2 Non-amplified But HER2 Mutant Breast Cancer (H-36359)
    • This phase II study will test cancer to see if it has a HER2 mutation and, if so, see how HER2 mutated cancer responds to treatment with neratinib.
  • NexTSTEPS Study (H-39002)
    • The purpose of this study is to evaluate a program that we have developed for advanced cancer patients and their family caregivers.